Intramuscular synthol injections cause hypercalcemia in long-term observation: a case report study

Hypercalcemia represents a prevalent and clinically significant ionic imbalance characterized by serum calcium concentrations exceeding the standard threshold of 10.5 mg/dL. Prior research has shown that primary hyperparathyroidism and various malignancies constitute the most frequent underlying etiologies for this metabolic disturbance in the majority of clinical cases. Elevated calcium levels exert profound systemic effects, potentially damaging nearly every organ system and presenting life-threatening risks if the underlying cause remains unmanaged. Clinical presentations often involve non-specific symptoms such as general weakness, fatigue, and unexplained weight loss, which frequently complicate the initial diagnostic trajectory for attending physicians. Acute kidney injury frequently emerges as a severe and debilitating complication when calcium homeostasis remains severely disrupted over extended periods of time. The physiological impact of excess calcium involves the renal, neurological, and cardiovascular systems, necessitating a rapid and accurate identification of the calcium source. This absence of evidence motivated the investigation into rare, non-traditional triggers that bypass standard endocrine or oncological screening protocols during the diagnostic process.

This case report identifies the causal relationship between long-term muscle enhancement practices and severe metabolic derangements involving calcium homeostasis. The investigation seeks to resolve the diagnostic mystery of a 60-year-old male presenting with acute kidney injury, general weakness, and significant weight loss. Clinicians aimed to systematically exclude common triggers such as sarcoidosis, endocrine dysfunction, and iatrogenic medication-related causes through a rigorous screening process. The study focuses on determining the specific source of elevated serum calcium when standard laboratory results and imaging findings remain inconclusive or negative. Researchers intended to document the clinical progression of a patient suffering from unidentified hypercalcemia following historical substance use for cosmetic purposes. The medical team sought to establish a definitive link between the presence of foreign oils in muscle tissue and systemic ionic shifts that led to renal failure. This report clarifies the necessity of muscle tissue examination in cases where systemic symptoms suggest an occult inflammatory or foreign body reaction.

Diagnostic protocols involved a comprehensive physical examination and detailed patient history to identify potential environmental, behavioral, or historical substance exposures. Laboratory technicians performed extensive blood chemistry panels and 24-hour urine collection to quantify calcium excretion levels and assess overall renal function. Radiologists used computed tomography to screen for internal malignancies, lymphadenopathy, or structural abnormalities within the thoracic and abdominal cavities. Gastroenterologists conducted endoscopy to rule out occult gastrointestinal sources of weight loss or metabolic interference that might mimic hypercalcemic symptoms. Pathologists executed a targeted muscle biopsy to examine the structural integrity of the tissue and identify any foreign substances or inflammatory markers. The team analyzed the histological samples to detect the presence of oil-induced granulomas or other pathological changes connected to synthol use. These multi-modal findings allowed the medical team to isolate the trigger of the patient's acute kidney injury and systemic metabolic imbalance.

Muscle biopsy results confirmed that synthol intramuscular injections served as the direct trigger for the patient's elevated serum calcium levels and subsequent metabolic distress. Serum calcium concentrations exceeded the diagnostic threshold of 10.5 mg/dL, leading to systemic toxicity and significant renal impairment in the 60-year-old subject. Clinical evaluation revealed that the patient suffered from acute kidney injury alongside significant weight loss and general physical weakness throughout the observation period. Systemic screening successfully ruled out primary hyperparathyroidism, sarcoidosis, and various malignancies as potential drivers of the observed ionic disorder. Imaging and endoscopic procedures failed to identify any iatrogenic or medication-related causes for the metabolic imbalance, narrowing the search to the muscular system. The biopsy provided the definitive evidence required to link the intramuscular foreign body to the systemic hypercalcemic state through histological identification. These findings established that foreign body reactions to the injected oil persisted long after the initial administration, causing delayed systemic effects.

Intramuscular synthol injections represent a significant, though rare, risk factor for developing chronic hypercalcemia and secondary organ damage in long-term users. Surgical resection of the synthol deposits appears to be the only effective therapeutic intervention for resolving the associated metabolic disturbances and preventing further renal decline. Clinicians must maintain a high index of suspicion for body modification substances when encountering unexplained ionic disorders in aging populations with a history of bodybuilding. Prompt diagnosis remains essential to prevent the progression of acute kidney injury into irreversible renal failure or other life-threatening complications. Future diagnostic frameworks for hypercalcemia should incorporate detailed histories regarding muscle-enhancing substances to avoid delayed treatment and unnecessary oncological screening. The study emphasizes that the long-term physiological consequences of synthol use extend far beyond localized tissue changes and can manifest as systemic metabolic crises. This case highlights the potential for late-onset systemic toxicity resulting from historical cosmetic or athletic enhancements performed decades earlier.